Publications

  1. Acuno J et al. (2014) TCTP as therapeutic target in cancers. Cancer Treatment Reviews (2014), 40, 760-769.
  2. Agarwal A et al. (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer Research (2014), 20(8), 2092-2103.
  3. Apostolidis S et al. (2016) Phosphatase PP2A is requisite for the function of regulatory T cells. Nature Immunology (2016), doi:10.1038/ni.3390.
  4. Bai X et al. (2014) Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Molecular Cancer Therapeutics (2014), 13(8), 2062-72.
  5. Bian Y et al. (2014) Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors. Proceedings of the National Academy of Sciences (PNAS) (2014), 111(4), 1628–1633.
  6. Brady R et al. (2013) An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain. Journal of Inherited Metabolic Disease (2013), 36, 451-454.
  7. Chang K et al. (2014) The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity. Molecular Cancer Therapeutics (2014), 14(1), 90-100.
  8. Chung V et al. (2017) Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors. Clinical Cancer Research (2017) DOI: 10.1158/1078-0432.CCR-16-2299.
  9. Chowdry RP et al. (2016) Phosphorylated Bcl-2 and Mcl-1 as prognostic markers in small cell lung cancer. Oncotarget (2016) Advanced Publications 2016
  10. Cristobal I et al. (2014) Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clinical Cancer Research (2014), 21(2), 347-56.
  11. Cui J et al. (2020) Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. Cancers (2020) 12, 139.
  12. D’arcy BM et al. (2019) Targeting phosphatases in cancer: suppression of many versus the ablation of one. Oncotarget. 2019; 10(61): 6543–6545.
  13. Feder A et al. (2014) Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder – A Randomized Clinical Trial. JAMA Psychiatry (2014), 71(6), 681-688.
  14. Galbo T et al. (2011) Free Fatty Acid-Induced PP2A Hyperactivity Selectively Impairs Hepatic Insulin Action on Glucose Metabolism. PLoS ONE (2011), 6(11), 1-9.
  15. Galbo T et al. (2013) PP2A inhibition results in hepatic insulin resistance despite Akt2 activation. Aging (2013), 5(10), 770-781.
  16. George J et al. (2015) Comprehensive genomic profiles of small cell lung cancer. Nature (2015), 524, 47-53.
  17. Gordon I et al. (2015) Protein phosphatase 2A inhibition with LB100 enhances radiation-induced mitotic catastrophe and tumor growth delay in glioblastoma. Molecular Cancer Therapeutics (2015), 14(7), 1540-47.
  18. Hao S et al. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro-Oncology. 2017; 20(6), 399-809.
  19. Ho et al. (2018) Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nature Communications (2018), 9:2126.
  20. Hong C et al. (2015) LB100, a Small Molecule Inhibitor of PP2A with Potent Chemo- and Radio-sensitizing Potential. Cancer Biology & Therapy (2015), 16(6), 821-33.
  21. Janssens V et al. (2012) The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells. Current Molecular Medicine (2012), 12, 268-287.
  22. Kalev P et al. (2011) Protein Phosphatase 2A as a Potential Target for Anticancer Therapy. Anti-Cancer Agents in Medicinal Chemistry (2011), 11, 38-46.
  23. Kauko O et al. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. J. Biol. Chem. 2020; 295(13) 4194-4211.
  24. Kelly GL et al. (2014) Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes & Development (2014), 28, 58-70.
  25. Lai D et al. (2014) Targeting TKI-Insensitive CML Stem/Progenitor Cells By Effective Inhibition of a Novel PP2A-AHI-1-BCR-ABL-JAK2 Complex. ASH Abstract (2014), Session: 603. Oncogenes and Tumor Suppressors: Poster I.
  26. Lecca et al. (2016) Rescue of GABAB and GIRK function in the lateral habenula by protein phosphatase 2A inhibition ameliorates depression-like phenotypes in mice. Nature Medicine (2016), 22(3), 254-61.
  27. Leverson JD et al. (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science Translational Medicine 7(279), 279ra.
  28. Lu J et al. (2010) The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. Journals of Neurosurgery (2010), 113(2), 225-33.
  29. Lu J et al. (2009) Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proceedings of the National Academy of Sciences (PNAS) (2009), 106(28), 11697–11702.
  30. Lu J et al. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proceedings of the National Academy of Sciences (PNAS) (2011), 108(52), 21200-5.
  31. Lu J. et al. (2013) Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. Proceedings of the National Academy of Sciences (PNAS) (2013), 110(26), 10747–10752.
  32. Lv et al (2014) Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair. Oncotarget (2014), 5(17): 7512–7524.
  33. Maggio D et al. Inhibition of protein phosphatase‐2A with LB‐100 enhances antitumor immunity against glioblastoma. 2020. Journal of Neuro-Oncology https://doi.org/10.1007/s11060-020-03517-5
  34. Martiniova L et al. (2011) Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS ONE (2011), 6(2), 1-8.
  35. Mazhar S et al. Targeting PP2A in cancer: Combination therapies. Biochimica et biophysica acta Molecular cell research 2019; 1866(1): 51-63.
  36. McDermott M et al. (2014) PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Molecular Cancer (2014), 13(157), 1-12.
  37. Mirrione M et al. (2014) Increased metabolic activity in the septum and habenula during stress is linked to subsequent expression of learned helplessness behavior. Frontiers in Human Neuroscience (2014), 8(29), 1-8.
  38. Nifoussi SK et al. (2014) Inhibition of protein phosphatase 2A (PP2A) preents Mcl-1 protein dephosphorylation at the Thr-163/ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells. J Biol Chem (2014), 289(32), 21950-21559.
  39. Proulx C et al. (2014) Reward processing by the lateral habenula in normal and depressive behaviors. Nature Neuroscience (2014), 17(9), 1-8.
  40. Sallman D et al. (2014) PP2A: the Achilles heal in MDS with 5q deletion. Frontiers in Oncology (2014), 4(264), 1-7.
  41. Sangodkar J et al (2016) All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS Journal (2016), 283, 1004-1024.
  42. Schramm K et al. (2019) DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas. Neuro-Oncology (2019), 21(7):867-877.
  43. Schvartzman J et al. (2011) Mad2 is a Critical Mediator of the Chromosome Instability Observed upon Rb and p53 Pathway Inhibition. Cancer Cell (2011), 19(6), 701–714.
  44. Seshacharyulu P et al (2013) Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. (2013), 335(1): 9-18.
  45. Switzer C et al. (2011) Targeting SET/I2PP2A Oncoprotein Functions as a Multi-pathway Strategy for Cancer Therapy. Oncogene (2011), 30(22), 2504–2513.
  46. Thebault S et al. (2016) TCTP contains a BH3-like domaine, which instead of inhibiting, activates Bcl-xL.Scientific Reports 6:19725 DOI: 10.1038, srep19725
  47. Teft W et al. (2009) Structure-Function Analysis of the CTLA-4 interaction with PP2A. BMC Immunology (2009), 10, 10-23.
  48. Uddin MH et al. (2020) Targeting PP2A inhibits the growth of triple- negative breast cancer cells. Cell Cycle (2020) 19:5, 592-600.
  49. Wei D et al. (2013) Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair. Clinical Cancer Research (2013), 19(16), 4422-32.
  50. Xian L et al. (2015) Liver‐specific deletion of Ppp2cα enhances glucose metabolism and insulin sensitivity. Aging (2015), 7(4), 223-232.
  51. Yang C et al. (2013) Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proceedings of the National Academy of Sciences (PNAS) (2013), 110(3), 966-71.
  52. Zhang S et al. (2008) Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma. Human Pathology (2008), 39, 1827–1834.
  53. Zhang C et al. (2010) A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma. Biomaterials (2010), 31(36), 9535-43.
  54. Zhuang Z et al. (2009) Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell Cycle (2009), 8(20), 3303-3306.